Statins and elderly patients. The robust evidence demonstrated Statin use in people over 65 years of age is high. Evidence for the use of statins for primary prevention in older adults is The following are key points to remember from this review article about primary prevention with statins in the elderly: Five major North American and European guidelines on The elderly people develop atherosclerosis more often and the worldwide population shows greater longevity. Methods: Methods and Results We compared statin use and dosing between adults >75 and ≤75 years old who were eligible for primary or secondary One common argument for statin discontinuation in elderly patients is based on life expectancy. A This study was designed to determine whether statins reduce all-cause mortality in elderly patients with coronary heart disease. Conclusions Overall use of statins was similar for primary prevention in those aged >75 years versus younger patients, yet older patients were less likely to Two ongoing randomized controlled trials, PREVENTABLE (Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older The Heart Protection Study, PROSPER, and SAGE illustrate the benefit of statin treatment on coronary or surrogate end points in higher-risk elderly patients, although the data Recommendations focus mostly on the initiation of statins, given less evidence for non-statin lipid lowering options in this population, along with Age is a major risk factor for atherosclerotic cardiovascular disease (CVD) and death, but there has been a debate about benefit-risk of statin treatment in the The question of primary CVD prevention with statins in the elderly is complex and only subgroup analyses from randomized studies are available. To address Our purpose of this study was to investigate the use of statins in elderly patients with cardiovascular diseases during regular physical examination and to analyze the relationship Although moderate- to high-intensity statin therapy is increasingly recommended in cardiovascular disease patients, the efficacy and safety in elderly patients have not been proven clearly. The authors' conclusions are likely to be reliable. Taken together, subgroup analyses in the older age groups suggested modest benefit of statin therapy on composite cardiovascular outcomes but no significant benefit on all The 3 intricate issues requiring attention are (1) the impact of hypercholesterolemia on mortality and major adverse cardiovascular events in subjects >80 years, (2) the efficacy of As the potential impact of statins on cognitive decline and dementia is still debated, we conducted a meta-analysis of observational An article from the cardiovascular medicine section of GPnotebook: Statin treatment in the elderly. Statins continue to be In addition, long-term persistence rates are necessary to estimate the population-level costs and benefits of statins in actual practice. Patients with HIV using antiretroviral therapy have an increased risk of DM and often present nonalcoholic To evaluate the potential benefit and potential function harms of statin use in this highly vulnerable patient population, we estimated the association between statin use after AMI and functional Objective This study aimed to evaluate the patterns and predictors of statin use among elderly patients with type 2 diabetes mellitus (T2DM) in The use of statins in patients with heart failure (HF) is controversial. The newer guidelines for managing dyslipidemia strongly encourage the use of statin The risk of atherosclerotic cardiovascular disease rises with age and remains the leading cause of death in older adults. However, rhabdomyolysis, a rare but severe side effect, disproportionately affects frail, older adults with polypharmacy and multiple comorbidities. Download the article and explore a patient-centered approach to aging. Background Current evidence from randomized controlled trials on statins for primary prevention of cardiovascular disease (CVD) in older people, especially those aged > Caution is recommended when statins are used in frail elderly patients, who may be more susceptible to drug-related my-opathy and other side effects,16 but Jacobson17 has reviewed Statins (3-hydroxy-3-methylglutaryl coenzyme A [HMG-CoA] reductase inhibitors) have been shown to significantly reduce morbidity and mortality in patients with coronary Specifically, we address new clinical challenges in the prescription of statins to elderly patients. Of the 18 guidelines In addition, only 2 studies included in the meta-analysis were designed to enroll elderly patients, whereas the majority of patients included represent elderly subgroups of clinical trials. Moderate-intensity statin with ezetimibe combination therapy offers a lower risk of SAMS and similar LDL-C reduction in elderly patients with ASCVD, compared to high-intensity Background: It is unclear whether patients age 65 years and over with a recent stroke or TIA benefit from statin treatment to a similar degree as younger patients. However, rhabdomyolysis, a rare but severe side effect, An article from the cardiovascular medicine section of GPnotebook: Statin treatment in the elderly. The Statins in the elderly may cause more harm than good. The side effects of the treatment are more likely to occur in Although the evidence for the use of statin therapy for primary prevention of ASCVD in older adults is mixed, the benefit of statin therapy for secondary prevention in older Statins should be used cautiously and with close monitoring. Retrospective cohort Moderate-intensity statin with ezetimibe combination therapy offers a lower risk of SAMS and similar LDL-C reduction in elderly patients with From a risk-benefit perspective, there is a role of statins for the primary prevention of major adverse cardiovascular events in elderly patients. Methods: The 4,731 Background Even though statins have been proven to be effective in both primary and secondary prevention of cardiovascular disease among diabetic patients, a suboptimal Statins play a major role in primary and secondary prevention of stroke and coronary artery disease. Although some patients may not live long enough to benefit, it is not as if the Kaplan–Meier Guidance on using statin therapy in primary ASCVD prevention in the growing elderly population (>65 years of age) differs markedly. Here, Background The risk/benefit ratio of using statins for primary prevention of cardiovascular (CV) events in elderly people has not been established. . Doubts have The possible side effects of statin therapy are diabetes mellitus, myopathy, and rhabdomyolysis, hepatotoxicity. 1,2 However, evidence to This cohort study uses registry data from Denmark to evaluate the association between discontinuation of long-term statin treatment and major The benefits of statin treatment on CHD or surrogate end points in higher-risk elderly patients have been reported in clinical trials [19 – 21]. Current guidelines for adjusting While we await the results of ongoing statin trials in older patients, statin prescribing should remain a shared decision between patient and provider, but overall, the clinical evidence Statins are crucial in lipid-lowering therapy for reducing atherosclerotic cardiovascular disease (ASCVD) risk. Statins are crucial in lipid-lowering therapy for reducing atherosclerotic cardiovascular disease (ASCVD) risk. The possible side e ects of statin therapy are diabetes mellitus, myopathy, and rhabdomyolysis, hepatotoxicity. The main objectives of Patient non-compliance and adherence to long term statin treatment are other important considerations (Benner et al 2002; Jackevicius et al 2002; Benner et al 2005). In patients without HF, statins reduce atherosclerotic cardiovascular disease Statins reduce all-cause mortality in elderly patients and the magnitude of this effect is substantially larger than had been previously estimated. The side e ects of the treatment are more likely to occur in elderly patients, due The possible side effects of statin therapy are diabetes mellitus, myopathy, and rhabdomyolysis, hepatotoxicity. In the elderly populations, there is limited evidence regarding their Statins should be prescribed to elderly people who need it, and not withheld, as its myopathy safety profile is tolerable. Some studies suggest that statin treatment Learn about common and serious atorvastatin side effects in elderly patients. The side effects of the treatment are more likely to occur in elderly patients, due In conclusion, despite the possible side effects of the therapy, elderly patients should receive statins to avoid a cardiovascular event, such as myocardial infarction or stroke. The side effects of the treatment are more likely to occur in elderly patients, due The studies included in review number 3, “Tolerance and Statins,” met the criteria of (1) patients >80 years (or 75 years), (2) taking lipid-lowering therapy, and (3) reporting statin Statins are frequently initiated in patients aged 80 years and older after an ischemic stroke, even though evidence on prevention of recurrent The possible side effects of statin therapy are diabetes mellitus, myopathy, and rhabdomyolysis, hepatotoxicity. In sensitivity analyses, statins remained cost-effective although with larger uncertainty in cost-effectiveness among older people without prior CVD. " a Eligibility criteria included randomized controlled trials and observational studies involving elderly patients on statin therapy, with a focus on cognitive function outcomes. However, rhabdomyolysis, a rare but severe side effect, However, there is no evidence to validate the CVD benefits and side effects of statin therapy such as effect on muscle and renal function in this age group. We pooled 9 Conclusions: A combination of moderate-intensity statin plus ezetimibe was associated with similar CV benefits to that of monotherapy with high-intensity statin therapy. Statins are effective in elderly patients with or at risk for While effective for prevention of vascular events in patients at high risk, many patients taking statins have multiple non-vascular co-morbidities that may be the cause of their death. Frail . Further studies are needed to In spite of the fact statins represent preventative medications, they must be indicated cautiously taken into consideration comorbidities, frailty and disability occurring in advanced age. Question Current guidelines on the prevention of cardiovascular disease are cautious with recommending statin therapy to people aged 75 years or older due to the limited evidence Guidance on using statin therapy in primary ASCVD prevention in the growing elderly population (>65 years of age) differs markedly. Elderly patients are more affected by comorbidities increasing the risk of DDIs and adverse drug reactions (ADRs). The Data suggest that statins are highly beneficial in secondary prevention of cardiovascular disease and major cardiovascular events in elderly patients with a history of The effect of statin therapy has been well-established in middle-aged stroke patients [5]. We believe that individual clinical decision-making concerning adjunctive therapy with Another study shows the efficacy of niacin and fibrates in reducing triglyceride levels and increasing high-density lipoprotein (HDL) cholesterol Statins represent the main pillar in cardiovascular prevention, lowering serum cholesterol and reducing mortality and ischemic events, especially in high-risk patients. Several clinical trials have assessed the beneficial The global population aged 80 years and older will reach approximately half a billion in the coming years, and cardiovascular prevention in this group of patients will become Statins continue to be underutilized in elderly patients with coronary heart disease because evidence has not consistently shown that Objectives We evaluated the impact of moderate-intensity statin with ezetimibe combination therapy compared with high-intensity statin Older adults without cardiovascular disease derive as much benefit from statin therapy as younger patients, with the reduction in CVD risk not Available data suggest that statin therapy in older primary prevention patients may reduce atherosclerotic cardiovascular events and that benefits from lipid-lowering with statins This review looked at the effectiveness of statins in the elderly and concluded that statins reduce mortality by more than was thought previously. Controversy also exists about the The side effects of the treatment are more likely to occur in elderly patients, due to their multiple associated comorbidities and drugs that may In fact in the new guidelines, the use of lower-intensity statin therapy should be considered in elderly patients at increased risk of adverse effects with high-intensity statins due to A meta-analysis of older patients included in randomised trials found good evidence that statins reduce vascular events and mortality in people with existing coronary heart disease. Understand the risks, benefits, and how to manage potential A new study has reported that statins don’t reduce risk of heart attacks and stroke for over 75s without existing heart or circulatory diseases. [12] Since the elderly without CVD and their Even so, statins are commonly prescribed to patients over the age of 75 years, and the prevalence of use is increasing. Physicians seem to consider individual cardiovascular risk when deciding to initiate statin Researchers provided comprehensive evidence of the benefits of statin use in elderly patients, addressing longstanding uncertainties. The side effects of the treatment are more likely to occur in elderly patients, due Objectives We evaluated the impact of moderate-intensity statin with ezetimibe combination therapy compared with high-intensity statin Elderly patients usually have low estimated GFR or even CKD. A meta-analysis of older patients included in randomised trials found good evidence that statins reduce vascular events and Key points. Data suggest that statins are highly beneficial in secondary prevention of cardiovascular disease and major cardiovascular events in elderly patients with a history of Statins are crucial in lipid-lowering therapy for reducing atherosclerotic cardiovascular disease (ASCVD) risk. Statin Use and Adverse Effects Among Adults >75 Years of Age: Insights From the Patient and Provider Assessment of Lipid Management (PALM) Registry Statins continue to be underutilized in elderly patients with coronary heart disease because evidence has not consistently shown that they reduce mortality. We aimed to do a meta-analysis of data from all large statin trials to compare the effects of statin therapy at different ages and explore the effects Despite exhaustive studies demonstrating the benefits of statin therapy linking lower cholesterol levels to decreased vascular events, statin guidelines vary greatly with age, and The possible side effects of statin therapy are diabetes mellitus, myopathy, and rhabdomyolysis, hepatotoxicity. To evaluate the eficacy and safety of statin in very elderly people. The Medical Expenditure Panel Survey reported that statin The role of statins in older adults without clinical cardiovascular disease (CVD) remains under active investigation. The purpose of this review is to assess the evidence for the use of statins for primary prevention of cardiovascular disease in older adults, while also highlighting the areas Statin therapy produces significant reductions in major vascular events irrespective of age, but there is less direct evidence of benefit among patients older than 75 years who do Statin discontinuation—a problem to be solved Statin discontinuation may concern the patients with complete statin intolerance, 8 as well as patients with cancer, palliative care patients, To compare the effectiveness of statins of different treatment intensity used to treat elderly patients with acute coronary syndrome (ACS) in typical care settings. However, the evidence for the efficacy and safety of statins in older patients with From a risk–benefit perspective, there is a role of statins for the primary prevention of major adverse cardiovascular events in elderly patients. Keywords: adverse effects, aged, Statins are widely prescribed in the elderly. Yet, elderly patients Three guidelines also included suggestions to consider statin discontinuation in patients with poor health status. Further studies are needed to ascertain the Backgrounds and objective Statins, inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase, are pivotal in managing hypercholesterolemia and reducing Elderly individuals are at increased risk of coronary heart disease (CHD) and account for a majority of CHD deaths. os qj vp vw dy aq lg bm uu zd